Projects
Preclinical and clinical assessment of the beneficial effects of hepcidin, a pivotal endogenous regulator of iron metabolism, on anthracycline-induced cardiotoxicity. KU Leuven
Mitochondrial iron overload in cardiac myocytes is associated with anthracycline-induced cardiotoxicity due to excess reactive oxygen species generation. Cancer can induce an inflammatory state, characterized by the inability of the organism to deliver stored iron to metabolizing tissues due to high circulating hepcidin levels (‘hepcidin block’). We are investigating the beneficial role of hepcidin on anthracycline-induced cardiotoxicity, ...
Discovering the role of titin (TTN) in anthracycline-induced cardiotoxicity in breast cancer. University of Antwerp
From Onco to Cardio: AGEs as a new target for chemotherapyinduced cardiotoxicity. Hasselt University
Risk prediction and modeling of cancer therapy related cardiotoxicity KU Leuven
The emergence of an ever-growing number of cancer therapies had a significant impact on cancer survival rates and converted a terminal illness into a chronic disease. Unfortunately, cancer treatment success has been offset by increased morbidity and mortality due to treatment related comorbidities. Cardiovascular complications are among the most serious side effects, sometimes not becoming manifest until many years after completion of ...
Analysing and Modulating Apoptosis Sensitisation and Resistance in Cultured and Patient-Derived Cardiac Cells by Quantitative Biochemistry and Computational Systems Biology Implications to Cardiotoxicity and Differentiation. KU Leuven
Cancer treatment during pregnancy: preclinical and clinical assessment of fetal cardiotoxicity KU Leuven
Chemotherapy-induced cardiotoxicity: time for a chAnGE of stRAteGiEs. Hasselt University
Assessment of Mechanical Dyssynchrony as Selection Criterion for CRT Treatment KU Leuven
Cardiac resynchronization therapy is an accepted treatment for patients with heart failure and conduction delays, where the contraction of the left ventricular chamber is re-synchronized by means of a dedicated pacemaker device with several electrodes. Current guideline criteria for selecting patients, however, result in a non-responder rate of approximately 35%. Some studies suggest that such non-responders are even at higher risk because of ...